Sodium-Glucose Co-transporter 2 Inhibitors treatment improve pancreatic β-cells function and insulin resistance in patients with Type 2 diabetes

被引：1
|
作者：
Shi, Fang-Hong [1 ]
Xu, Li [2 ]
Shen, Long [2 ]
Cao, Min-Jia [1 ]
Li, Hao [3 ]
机构：
[1] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Pharm, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Clin Res Ward, Clin Res Ctr, Shanghai Childrens Med Ctr,Sch Med, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2024年 / 130卷
关键词：
DOUBLE-BLIND; SENSITIVITY;
D O I：
10.1016/j.ejim.2024.07.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：182 / 184
页数：3
相关论文
共 50 条
  • [41] Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials
    Boeder, Schafer
    Edelman, Steven V.
    DIABETES OBESITY & METABOLISM, 2019, 21 : 62 - 77
  • [42] Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
    Cersosimo, Eugenio
    Miles, John M.
    CURRENT DIABETES REVIEWS, 2019, 15 (04) : 314 - 327
  • [43] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Torimoto, Keiichi
    Okada, Yosuke
    Koikawa, Kenji
    Tanaka, Yoshiya
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [44] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Keiichi Torimoto
    Yosuke Okada
    Kenji Koikawa
    Yoshiya Tanaka
    Diabetology & Metabolic Syndrome, 9
  • [45] Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes
    Oldgren, J.
    Laurila, S.
    Akerblom, A.
    Latva-Rasku, A.
    Rebelos, E.
    Isackson, H.
    Saarenhovi, M.
    Eriksson, O.
    Heurling, K.
    Johansson, E.
    Wilderang, U.
    Karlsson, C.
    Ferrannini, E.
    Oscarsson, J.
    Nuutila, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S62 - S63
  • [46] Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function
    Shi, Fang-Hong
    Li, Hao
    Shen, Long
    Xu, Li
    Ge, Heng
    Gu, Zhi-Chun
    Lin, Hou-Wen
    Pu, Jun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (04): : 1191 - 1203
  • [47] Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes
    Tosaki, Takahiro
    Kamiya, Hideki
    Himeno, Tatsuhito
    Kato, Yoshiro
    Kondo, Masaki
    Toyota, Kaori
    Nishida, Tomoyo
    Shiroma, Megumi
    Tsubonaka, Kaori
    Asai, Hitomi
    Moribe, Miho
    Nakaya, Yuki
    Nakamura, Jiro
    INTERNAL MEDICINE, 2017, 56 (06) : 597 - 604
  • [48] Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure
    Takenaka, Tsuneo
    Ohno, Yoichi
    Suzuki, Hiromichi
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (02): : 154 - 157
  • [49] Sodium-glucose co-transporter type-2 inhibitors: is the message getting through?
    Charlesworth, M.
    Feddy, L.
    Wisely, N.
    ANAESTHESIA, 2019, 74 (05) : 679 - 679
  • [50] Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes
    Kushner, Pamela
    WOMENS HEALTH, 2016, 12 (03) : 379 - 388
12345